Ileana Esparraguera, MD
General Practice · Washington, DCNPI 1821155938
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $6,650 of the $7,874 with a category attached, or 84.5%. It is spread thinly across 39 manufacturers, the largest accounting for just 16.9% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $2,411 and has fallen 64.3% since, to $861 in 2025. Among general practice clinicians in DC with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 376 payments — averaging $20.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Biohaven Pharmaceuticals, Inc.$1K
- AbbVie$1K
- Lilly USA, LLC$752
- Novo Nordisk$667
- Pfizer$532
- Merck$399
- plus $3K from 33 others
What the payments were for
- Consulting fees$1,20015%
- Food & beverage$6,65084%
- Education$240%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NURTEC ODT$1,200
- Ozempic$216
- VOQUEZNA$111
How this compares
$7,874 in reported general payments places this provider in the 95th percentile of 272 general practice providers in District of Columbia.
See all general practice providers in District of Columbia →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RybelsusSemaglutide | 16 | $40,049 |
| OzempicSemaglutide | 15 | $13,586 |
| NexlizetBempedoic Acid/Ezetimibe | 15 | $10,485 |
| Nebivolol Hcl | 44 | $2,565 |
| Olmesartan Medoxomil | 76 | $2,548 |
| Rosuvastatin Calcium | 101 | $2,361 |
| Olmesartan-HydrochlorothiazideOlmesartan/Hydrochlorothiazide | 43 | $1,963 |
| Risedronate Sodium | 12 | $1,090 |
| Atorvastatin Calcium | 64 | $1,050 |
| ValacyclovirValacyclovir Hcl | 22 | $941 |
| Celecoxib | 14 | $479 |
| Levothyroxine Sodium | 20 | $418 |
| Nifedipine ErNifedipine | 11 | $405 |
| Metformin Hcl | 32 | $367 |
| Metoprolol Tartrate | 18 | $247 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskRybelsus, Ozempic | $667 | $53,63531 claims |
| Esperion Therapeutics, Inc.Nexlizet | $246 | $10,48515 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 272 general practice providers in District of Columbia.
Other general practice in Washington
- Brian GrayWashington$217K
- Fahad AshrafWashington$39K
- Shila YazdaniWashington$11K
- Roman MossWashington$11K
- John TsaknisWashington$10K
- Brian ChangWashington$8K
- Sheila SamaddarWashington$7K
- Sinclair DavisWashington$6K
- Christina MillsWashington$4K
- Stephanie SimmonettWashington$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.